Crescita Therapeutics Inc.
CRRTF
$0.54
$0.00-0.37%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 9.09% | -13.08% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 9.09% | -13.08% | |||
| Cost of Revenue | 27.41% | 5.88% | |||
| Gross Profit | -7.19% | -25.02% | |||
| SG&A Expenses | 28.81% | -8.80% | |||
| Depreciation & Amortization | -191.07% | 9.29% | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 12.68% | -1.23% | |||
| Operating Income | -132.40% | -127.91% | |||
| Income Before Tax | -192.10% | -5.22% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -193.29% | -5.22% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -193.29% | -5.22% | |||
| EBIT | -132.40% | -127.91% | |||
| EBITDA | -150.93% | -76.17% | |||
| EPS Basic | -194.48% | -4.92% | |||
| Normalized Basic EPS | -103.61% | 31.05% | |||
| EPS Diluted | -194.48% | 0.35% | |||
| Normalized Diluted EPS | -103.61% | 31.75% | |||
| Average Basic Shares Outstanding | -1.18% | -0.51% | |||
| Average Diluted Shares Outstanding | -1.25% | -0.99% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||